Zelboraf (Vemurafenib)

Save up to 50% on brand name Zelboraf from Europe.

Non-english packaging is often present for European medicines- English label and English insert included. Plan in advance - allow us 7 days to ship this brand name medicine.

According to the European Medicines Agency, brand name Zelboraf originating from Europe is manufactured at the following site(s): Roche Pharma AG Emil-Barell-Strasse 1 D-79639 Grenzach-Wyhlen Germany

Information about Zelboraf (Vemurafenib)

Zelboraf (Vemurafenib) is a medication primarily used in the treatment of melanoma, a type of skin cancer. It is a targeted therapy that works by inhibiting the activity of the BRAF V600E mutation, which is commonly found in melanoma cells. By targeting this specific mutation, Zelboraf helps slow the growth and spread of cancer cells, improving outcomes for patients with advanced melanoma.

Product Highlights

• Zelboraf is primarily indicated for the treatment of metastatic melanoma or unresectable melanoma with the BRAF V600E mutation. It is used to treat advanced cases of melanoma when surgery is not an option.
• It may also be used off-label for other cancers that express the BRAF V600E mutation, but it is most commonly used for melanoma.

Key Ingredient

• Vemurafenib

Key Benefits

• Zelboraf is specifically designed to target the BRAF V600E mutation, which is present in about half of melanoma cases, offering a more personalized and effective treatment option.
• Studies have shown that treatment with Zelboraf improves progression-free survival in patients with metastatic melanoma, meaning it helps delay cancer progression and increase the chances of long-term survival.
• Zelboraf is taken orally in pill form, making it a convenient treatment option compared to some other cancer therapies that require injections or intravenous administration.
• Zelboraf is effective in treating advanced melanoma that cannot be surgically removed, helping to manage the disease and slow its progression.

Direction of Use

• The typical dose of Zelboraf for adults is 960 mg (4 tablets of 240 mg) taken twice daily, in the morning and evening.
• Take the tablet orally, with or without food. Swallow the tablets whole; do not split, crush, or chew them. 
• Take at the same time each day to maintain consistent levels of the drug in your system.
• If you miss a dose, take it as soon as you recall, unless it's almost time for your next dose. Do not take a double dose to compensate for the missed one. 

Safety Concerns

• Side effects of Zelboraf may include joint pain, rash, fatigue, nausea, and skin reactions.
• Some serious side effects include QT prolongation (a heart rhythm problem), liver issues, skin problems, and potential for developing a second cancer (such as squamous cell carcinoma).
• Zelboraf can cause severe skin reactions, including rashes, photosensitivity (sensitivity to sunlight), and skin cancers (such as non-melanoma skin cancers). Patients should be advised to protect their skin from sun exposure.
• Zelboraf can lead to heart problems such as QT prolongation, which can increase the risk of serious heart arrhythmias. Regular heart monitoring may be necessary during treatment.
• Liver function should be monitored during treatment, as liver toxicity is a potential side effect of vemurafenib.
• Vemurafenib may interact with other medications, so it's important to inform your healthcare provider about all medications, including over-the-counter drugs, supplements, and herbal products.

Avoid Zelboraf (Vemurafenib) If

• Avoid Zelboraf if you are allergic to vemurafenib or any of its ingredients.
• Zelboraf is not recommended during pregnancy or breastfeeding, as it may harm the developing fetus or infant. Women of childbearing potential should use reliable contraception during treatment. 
• If you have severe liver problems, Zelboraf should be avoided, or dosage adjustments may be required.
• If you have a history of QT prolongation or other significant heart problems, discuss with your doctor, as Zelboraf may increase the risk of arrhythmias.
• Avoid if you have a history of other skin cancers (such as squamous cell carcinoma) that might worsen with treatment, or if you have active skin cancer.
• Avoid using Zelboraf in combination with drugs that strongly inhibit or induce liver enzymes (such as certain antibiotics or antifungals), as this may alter the effectiveness or safety of Zelboraf.